JP2018526410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526410A5 JP2018526410A5 JP2018512604A JP2018512604A JP2018526410A5 JP 2018526410 A5 JP2018526410 A5 JP 2018526410A5 JP 2018512604 A JP2018512604 A JP 2018512604A JP 2018512604 A JP2018512604 A JP 2018512604A JP 2018526410 A5 JP2018526410 A5 JP 2018526410A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- azabicyclo
- endo
- octane
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052736 halogen Inorganic materials 0.000 claims description 90
- 150000002367 halogens Chemical class 0.000 claims description 90
- -1 3 -Methyl-1,2-thiazol-5-yl Chemical group 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 42
- 125000003545 alkoxy group Chemical group 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- 206010012289 Dementia Diseases 0.000 claims 6
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 4
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 3
- 206010044688 Trisomy 21 Diseases 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 claims 3
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 claims 2
- GDQYFKGLAUOXST-UHFFFAOYSA-N indolizin-2-amine Chemical compound C1=CC=CN2C=C(N)C=C21 GDQYFKGLAUOXST-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- QGCRJRVFQZXCAZ-UHFFFAOYSA-N 1h-triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC=CC2=CN(N)NN21 QGCRJRVFQZXCAZ-UHFFFAOYSA-N 0.000 claims 1
- FZAXBPZVVJOFKX-UHFFFAOYSA-N 3-methyl-1,2,4-oxadiazole Chemical compound CC=1N=CON=1 FZAXBPZVVJOFKX-UHFFFAOYSA-N 0.000 claims 1
- KMOCWZDDMSUAPI-UHFFFAOYSA-N 8-(2,3,4-trifluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound NC1=NN2CCCC(C2=N1)C1=C(F)C(F)=C(F)C=C1 KMOCWZDDMSUAPI-UHFFFAOYSA-N 0.000 claims 1
- RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 0 CCCCC(CCCCCC[C@]1C=*C)CCC(C2)C2C1N(CC1CC2)CC2C1Nc1n[n](C(C)C(*)CC2C3=CC=C*(*)C=C3)c2n1 Chemical compound CCCCC(CCCCCC[C@]1C=*C)CCC(C2)C2C1N(CC1CC2)CC2C1Nc1n[n](C(C)C(*)CC2C3=CC=C*(*)C=C3)c2n1 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BSOVAWQWIYEOAI-UHFFFAOYSA-N 2-bromo-8-[4-(trifluoromethylsulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridine Chemical compound FC(F)(F)SC1=CC=C(C=C1)C1=CC=CN2N=C(Br)N=C12 BSOVAWQWIYEOAI-UHFFFAOYSA-N 0.000 description 1
- DLILBKMOUOQUPL-UHFFFAOYSA-N 5-(trifluoromethyl)-8-(2,3,4-trifluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound NC1=NN2C(CCC(C2=N1)C1=C(F)C(F)=C(F)C=C1)C(F)(F)F DLILBKMOUOQUPL-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15184480 | 2015-09-09 | ||
| EP15184480.0 | 2015-09-09 | ||
| PCT/EP2016/070800 WO2017042114A1 (en) | 2015-09-09 | 2016-09-05 | Bridged piperidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526410A JP2018526410A (ja) | 2018-09-13 |
| JP2018526410A5 true JP2018526410A5 (enExample) | 2019-09-26 |
| JP6831372B2 JP6831372B2 (ja) | 2021-02-17 |
Family
ID=54072754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512604A Active JP6831372B2 (ja) | 2015-09-09 | 2016-09-05 | 架橋ピペリジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10604517B2 (enExample) |
| EP (1) | EP3347363B1 (enExample) |
| JP (1) | JP6831372B2 (enExample) |
| CN (1) | CN107922437B (enExample) |
| AR (1) | AR105965A1 (enExample) |
| TW (1) | TWI716446B (enExample) |
| WO (1) | WO2017042114A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6831372B2 (ja) | 2015-09-09 | 2021-02-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋ピペリジン誘導体 |
| JP7012715B2 (ja) * | 2016-06-27 | 2022-01-28 | エフ．ホフマン－ラ ロシュ アーゲー | γ－セクレターゼモジュレーターとしてのトリアゾロピリジン |
| CN109689653B (zh) | 2016-09-09 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 用于制备2-(6-硝基吡啶-3-基)-9H-二吡啶并[2，3-b；3’，4’-d]吡咯的方法 |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| CN109476670B (zh) | 2016-10-04 | 2022-06-28 | 豪夫迈·罗氏有限公司 | 二环杂芳基衍生物 |
| EP3535266B1 (en) * | 2016-11-01 | 2021-12-29 | F. Hoffmann-La Roche AG | Bicyclic heteroaryl derivatives |
| WO2019121434A1 (en) * | 2017-12-18 | 2019-06-27 | F. Hoffmann-La Roche Ag | Triazolo-azepine derivatives |
| CN111417636B (zh) * | 2018-01-22 | 2023-09-26 | 豪夫迈·罗氏有限公司 | 三唑并-氮杂䓬衍生物 |
| TWI841592B (zh) | 2018-09-03 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環雜芳基衍生物 |
| LT3894411T (lt) * | 2018-12-13 | 2024-08-26 | F. Hoffmann-La Roche Ag | 7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo [1,2-b][1,2,4]triazol-2-amino dariniai ir susiję junginiai kaip gama sekretazės moduliatoriai alzheimerio ligai gydyti |
| US12275709B2 (en) | 2018-12-27 | 2025-04-15 | Hoffmann-La Roche Inc. | Process for the preparation of exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate |
| NZ780966A (en) | 2019-04-18 | 2026-02-27 | Univ Johns Hopkins | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof |
| IL301817A (en) | 2020-10-13 | 2023-06-01 | Univ Johns Hopkins | Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003068776A1 (ja) * | 2002-02-15 | 2005-06-02 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| AU2009216851B2 (en) * | 2008-02-22 | 2013-11-07 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| WO2009128669A2 (ko) * | 2008-04-16 | 2009-10-22 | 엘지이노텍주식회사 | 발광 소자 및 그 제조방법 |
| AU2009312856A1 (en) * | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
| TWI461425B (zh) * | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| CA2755467A1 (en) * | 2009-05-07 | 2010-12-23 | Janssen Pharmaceuticals, Inc. | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| WO2010138901A1 (en) * | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| EP2491524A4 (en) * | 2009-10-23 | 2014-10-01 | Apriva Llc | SYSTEM AND DEVICE FOR CONSOLIDATING SIM, PERSONAL TOKEN AND ASSOCIATED APPLICATIONS |
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) * | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| EP2687528A1 (en) * | 2012-07-17 | 2014-01-22 | Ares Trading S.A. | Fused triazole derivatives as gamma secretase modulators |
| JP6831372B2 (ja) | 2015-09-09 | 2021-02-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋ピペリジン誘導体 |
-
2016
- 2016-09-05 JP JP2018512604A patent/JP6831372B2/ja active Active
- 2016-09-05 CN CN201680051165.9A patent/CN107922437B/zh active Active
- 2016-09-05 WO PCT/EP2016/070800 patent/WO2017042114A1/en not_active Ceased
- 2016-09-05 EP EP16763491.4A patent/EP3347363B1/en active Active
- 2016-09-08 AR ARP160102743A patent/AR105965A1/es unknown
- 2016-09-08 TW TW105129076A patent/TWI716446B/zh not_active IP Right Cessation
-
2018
- 2018-03-06 US US15/913,087 patent/US10604517B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6267806B2 (ja) | ２，４−二置換ベンゼン−１，５−ジアミン誘導体およびその使用ならびにそれから製造される医薬組成物および薬用組成物 | |
| JP6643545B2 (ja) | Ｔｒｐｍ８拮抗剤としてのアザスピロ誘導体 | |
| US9751881B2 (en) | Inhibitors of the renal outer medullary potassium channel | |
| TWI543981B (zh) | 作為ｃ－ｋｉｔ激酶抑制劑之化合物及組合物 | |
| US8877742B2 (en) | Compounds | |
| TW202000667A (zh) | 藥學化合物 | |
| AU2009217356A1 (en) | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | |
| KR20250048267A (ko) | 암 치료를 위한 qpctl 및 qpct 억제제로서의 3-(6-피리딘-3-일)-2-[4-(4-메틸-4h-1,2,4-트리아졸-3-일)피페리딘-1-일]벤조니트릴 유도체 및 유사 화합물 | |
| TW200938201A (en) | Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof | |
| US11427578B1 (en) | Substituted pyrrolopyridine-derivatives | |
| WO2011149921A1 (en) | Soluble guanylate cyclase activators | |
| WO2015042497A2 (en) | Substituted aminopyrimidine compounds and methods of use | |
| US20170020879A1 (en) | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | |
| EP2788000A1 (en) | Pyrrolopyrimidines as janus kinase inhibitors | |
| JP2018536671A5 (enExample) | ||
| JP2004517070A5 (enExample) | ||
| US10023534B2 (en) | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | |
| JP2020114814A (ja) | ベンゾオキサゼピン化合物の作製方法 | |
| JP2021522262A5 (enExample) | ||
| JP2019535761A (ja) | 一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類 | |
| JP2019518079A (ja) | それに関連する障害の治療または予防に有用なβ−３アドレナリン受容体調節剤 | |
| KR20160022889A (ko) | 키나제 억제제로서 유용한 치환된 테트라히드로카르바졸 및 카르바졸 카르복스아미드 화합물 | |
| CA3002801A1 (en) | Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors | |
| JP7765556B2 (ja) | てんかん治療用複素環化合物 | |
| JP2009515918A (ja) | チアゾール誘導体、及びその使用 |